Evidence map›Paper›PMID 23184960›Full record

ArticleThe Journal of biological chemistry2013

Designing a soluble near full-length HIV-1 gp41 trimer.

Guofen Gao, Lindsay Wieczorek, Kristina K Peachman, Victoria R Polonis, Carl R Alving, Mangala Rao, Venigalla B Rao

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Guofen GaoDepartment of Biology, The Catholic University of America, Washington, DC 20064, USA.
Lindsay Wieczorek
Kristina K Peachman
Victoria R Polonis
Carl R Alving
Mangala Rao
Venigalla B Rao

Funding

Potent Phage T4 Derived V2 Immunogens as HIV VaccinesR01AI102725 · NIAID · CATHOLIC UNIVERSITY OF AMERICA · PI RAO, VENIGALLA B. · 2012 to 2015
$1.7M
NIAID NIH HHS R01AI02725NIAID NIH HHS R01 AI102725
6 · The paper itself

Abstract

The HIV-1 envelope spike is a trimer of heterodimers composed of an external glycoprotein gp120 and a transmembrane glycoprotein gp41. gp120 initiates virus entry by binding to host receptors, whereas gp41 mediates fusion between viral and host membranes. Although the basic pathway of HIV-1 entry has been extensively studied, the detailed mechanism is still poorly understood. Design of gp41 recombinants that mimic key intermediates is essential to elucidate the mechanism as well as to develop potent therapeutics and vaccines. Here, using molecular genetics and biochemical approaches, a series of hypotheses was tested to overcome the extreme hydrophobicity of HIV-1 gp41 and design a soluble near full-length gp41 trimer. The two long heptad repeat helices HR1 and HR2 of gp41 ectodomain were mutated to disrupt intramolecular HR1-HR2 interactions but not intermolecular HR1-HR1 interactions. This resulted in reduced aggregation and improved solubility. Attachment of a 27-amino acid foldon at the C terminus and slow refolding channeled gp41 into trimers. The trimers appear to be stabilized in a prehairpin-like structure, as evident from binding of a HR2 peptide to exposed HR1 grooves, lack of binding to hexa-helical bundle-specific NC-1 mAb, and inhibition of virus neutralization by broadly neutralizing antibodies 2F5 and 4E10. Fusion to T4 small outer capsid protein, Soc, allowed display of gp41 trimers on the phage nanoparticle. These approaches for the first time led to the design of a soluble gp41 trimer containing both the fusion peptide and the cytoplasmic domain, providing insights into the mechanism of entry and development of gp41-based HIV-1 vaccines.

Indexed as

Antibodies, MonoclonalAnti-HIV AgentsBiochemistryElectrophoresis, Polyacrylamide GelEnzyme-Linked Immunosorbent AssayEpitopesGenetic VectorsHIV-1HIV Envelope Protein gp41HIV Fusion InhibitorsMutagenesisMutationPeptide LibraryPeptidesProtein ConformationProtein FoldingAntibodies, MonoclonalAnti-HIV AgentsEpitopesHIV Envelope Protein gp41HIV Fusion InhibitorsPeptide LibraryPeptidesRecombinant Proteins

Identifiers

PMID23184960
PMCPMC3537018

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.